Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REEF-1: JNJ-73763989 and/or JNJ-56136379 in Chronic Hepatitis B
NCT03982186Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of tomligisiran and bersacapavir in Chronic Hepatitis B (CHB) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Meeting the Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at Week 48. Started Aug 2019; status: completed.
02
Drugs
tomligisiranbersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03982186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982186.